Connect with us

News

Leading healthtech companies building AI-powered medical software

Published

on

AI is now a practical tool in medicine, not science fiction. It’s automating tedious parts of diagnostics and personalizing treatment plans in ways that were too costly or slow before. This piece looks at the companies actually building these systems, the ones moving from prototypes to patient bedsides. It’s a review of who’s delivering real products right now.

Why AI is reshaping the healthtech industry

The pressure is coming from every side. Hospitals are drowning in data from imaging archives, genomic sequencers, and patient monitors. There simply aren’t enough specialists to analyze it all. AI steps in to do the initial heavy lifting, spotting patterns humans might miss because of fatigue or volume. It’s a response to a system cracking under its own complexity.

Several concrete factors are pushing adoption past the hype cycle:

  • The sheer explosion of medical data from imaging, genomics, and continuous monitors,
  • A global shortage of specialists, especially in radiology and pathology,
  • Demand for faster, more accurate diagnostic triage to improve outcomes,
  • The move towards value-based care, which needs predictive tools to prevent costly complications.

AI isn’t replacing doctors. It’s giving them a powerful assistant. The goal is to remove administrative drag and highlight critical cases faster, letting clinicians focus on the human parts of care. Frankly, the old way isn’t sustainable.

How to choose an AI healthtech development partner

Picking a team is everything. A mistake here can sink a project for years, burning cash and clinical goodwill. You need builders who know the medical world’s unique rules, not just generic software shops.

Key criteria to vet any potential partner:

  • Proven experience shipping clinical-grade software, not just demos;
  • Deep, practical knowledge of HIPAA, GDPR, and other medical data rules;
  • A track record of building systems designed for regulatory submissions like the FDA;
  • Strong, production-level expertise in machine learning operations and medical data engineering.

Ignore these points at your peril. According to our data, teams without this specific background get bogged down in compliance nightmares. They waste months re-architecting for security and audit trails that should have been there from day one. It’s a costly learning curve.

Top healthtech companies building AI-powered medical software

These firms represent the current vanguard. They’ve moved beyond research to create deployed, revenue-generating tools that are changing clinical workflows.

CHI Software

CHI Software operates as an international engineering firm with a sharp focus on applied AI for medicine. They provide healthcare ai consulting and development, translating clinical problems into functioning software. Their work spans diagnostic aids, predictive analytics, and automating hospital administrative tasks.

What they actually build:

  • Algorithms for analyzing medical images like X-rays and retinal scans;
  • Clinical prediction engines for patient deterioration or readmission risk;
  • Workflow integration tools that slot AI insights into existing hospital systems;
  • Secure, HIPAA-ready cloud infrastructure for sensitive health data.

Partnering with them offers a shortcut. You get a team that already understands the production stack for medical AI, from data anonymization pipelines to model monitoring in clinical settings. They handle the technical heavy lifting so clinical teams can validate and deploy.

Tempus AI

Tempus built a massive platform linking clinical and molecular data. They collect real-world evidence from oncologists and use AI to find patterns in treatment responses. It’s precision medicine at a commercial scale, now a publicly traded company.

Their strengths are foundational:

  • One of the largest curated databases of clinical and genomic profiles.
  • AI models that help match patients to therapies based on similar cases.
  • A commercially mature platform used by thousands of clinicians.

Their tools are particularly strong in oncology and cardiology, helping doctors make data-informed choices when standard pathways aren’t clear. It’s a big data approach to personalized care.

Zebra Medical Vision

Zebra Medical reads medical images automatically. Their algorithms scan X-rays, CTs, and MRIs for signs of disease, acting as a first pass for radiologists. The value proposition is straightforward: increase throughput and catch what’s easy to miss.

The platform’s advantages are clear:

  • Automated detection of dozens of conditions from liver disease to vertebral fractures.
  • It reduces the crushing workload on radiology departments.
  • Enables earlier diagnosis across a wide spectrum of common and rare diseases.

For hospitals with high patient volume, this isn’t just nice to have. It’s becoming essential infrastructure to keep reporting times down and quality high.

Aidoc

Aidoc specializes in the emergency room. Their AI analyzes CT scans in real-time, flagging critical conditions like intracranial bleeding, pulmonary embolisms, and cervical spine fractures. Speed is their main product.

Key reasons they’re adopted:

  • Algorithms focused on time-sensitive, life-threatening conditions.
  • They offer a suite of FDA-cleared tools.
  • Deployed in hundreds of hospitals worldwide to prioritize urgent cases.

Their system provides a safety net. It ensures the sickest patients get seen first by highlighting critical findings the moment a scan is complete, streamlining the triage process in chaotic ER environments.

Qure.ai

Qure.ai targets accessibility. They develop accurate, affordable AI tools for reading chest X-rays and head CTs, designed to work in low-resource settings where radiologists are scarce. Their mission is to widen access to quality diagnostics.

Their main capabilities include:

  • High-accuracy analysis of X-rays and CTs for TB, lung cancer, and stroke;
  • Solutions optimized for regions with limited internet or specialist access;
  • Coverage for pulmonary, neurological, and trauma-related pathologies.

Their focus on global health makes them a different kind of player. They prove that advanced medical AI doesn’t only belong in wealthy, tertiary-care hospitals.

Market outlook: what’s next for AI in healthcare?

The next phase is moving from point solutions to connected systems. We’ll see fewer standalone analysis tools and more AI baked directly into electronic health records and clinical workflows.

A few directions seem locked in:

  • More autonomous diagnostic systems for high-volume, routine screenings;
  • Sophisticated tools for designing truly personalized drug and therapy regimens;
  • AI models that integrate seamlessly with EMRs, providing insights at the point of care;
  • The cautious, regulated arrival of generative AI for clinical note summarization and patient communication.

This shift will demand new hospital IT infrastructure. The future is less about buying a single AI product and more about building an interoperable, AI-enabled data environment. The companies that solve for this integration will lead the next wave.

Conclusion

The AI HealthTech market is maturing past the pilot project. The companies reviewed here are building the new standard of care, where data-driven tools support every clinical decision. AI provides a tangible benefit: it makes healthcare systems more efficient and takes some weight off clinicians’ shoulders.

Choosing the right builder, one with medical-grade expertise, is the critical first step in turning that potential into a working product that helps patients. That’s the real goal.

 

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Fertility

GLP-1 drugs do not increase pregnancy risks, study finds

Published

on

GLP-1 drugs taken before conception were not linked to higher pregnancy risks in new research, which suggested they may even offer some protection.

Women of reproductive age are increasingly prescribed GLP-1 drugs for weight-management support, but the risks and benefits of using them before pregnancy remain poorly understood.

The findings support continuing the use of GLP-1 medicines in women with metabolic risk factors who are considering pregnancy, said Cara Dolin, a maternal-fetal medicine specialist and co-author of the research, which was presented at the Society of Maternal-Fetal Medicine pregnancy meeting in February 2026.

“While there’s more research to be done, this data provides some reassurance that it is not harmful to be taking a GLP-1 if you’re planning a pregnancy, and that having done so may in fact benefit you by optimising your preconception metabolic health.”

The researchers examined electronic medical records for patients with a pre-pregnancy BMI of more than 30 who delivered at more than 20 weeks’ gestation. The data were reviewed for two studies: one assessed the link between pre-pregnancy GLP-1 use and the risk of gestational diabetes, while the second looked at the risk of severe maternal morbidity in patients with obesity.

Women with obesity, diabetes, cardiovascular disease and other cardiometabolic disorders have a higher risk of pregnancy complications including preeclampsia, gestational diabetes, stillbirth, caesarean section and other outcomes. While GLP-1 medicines can help manage these conditions, they are contraindicated during pregnancy, and women are typically advised to stop the medication two months before trying to conceive.

However, stopping the drugs can often lead to rebound weight gain or worsening metabolic health. A 2025 study suggested this rebound worsened some pregnancy outcomes, but the risks and benefits are still poorly understood, Dolin said.

“There is a lot we just don’t know, which is why we wanted to look at our experience here with our Cleveland Clinic patients and see whether taking GLP-1 drugs before pregnancy was causing harm or if it was beneficial and helping patients have healthier pregnancies.”

Researchers analysed data for more than 8,000 women who had obesity but did not have diabetes before they became pregnant. They compared outcomes for 208 women who had been prescribed GLP-1 receptor agonists before pregnancy with those who had not been prescribed the medication.

Women in the GLP-1 group had more risk factors heading into pregnancy. They tended to be older and have a higher body mass index, higher rates of bariatric surgery and chronic high blood pressure, and present earlier for prenatal care.

However, outcomes for the two groups were similar. Researchers found that the GLP-1 group did not have higher rates of gestational diabetes, severe maternal morbidity or other adverse maternal outcomes, suggesting that the medication may have helped mitigate elevated risk factors.

“I think this is a really important signal, and it may reflect that these patients were able to optimise their metabolic health prior to conception.”

“It shows there’s potential to use these drugs in a more targeted way with patients who are planning a pregnancy and have these different comorbidities and obesity.”

While the findings suggest that using GLP-1 drugs before pregnancy may be beneficial in women with metabolic risk factors, having a plan to stop the medicines before conception is essential, Dolin noted. In some cases, patients may be moved to an alternative medication that is safe for pregnancy and can be used to help manage their metabolic health during pregnancy.

Providers with patients who are taking GLP-1 medicines and planning a pregnancy should consider referral to a maternal-fetal medicine specialist for pre-pregnancy counselling.

“We can have a nuanced conversation with the patient about taking the medication, what the benefits are, what the potential risks are, and help them formulate a plan to transition off the medication once they’re ready to start trying to conceive,” she said.

Continue Reading

Cancer

New scan could speed up endometriosis diagnosis

Published

on

Obesity may be a key driver of rising rates of 11 cancers in adults under 50, a study has found.

The 11 cancers were thyroid, multiple myeloma, liver, kidney, gallbladder, colorectal, pancreatic, endometrial, oral, breast and ovarian cancers.

All except oral cancer are known to be linked to excess weight, with researchers saying raised insulin levels and inflammation may play a part.

The findings come from researchers at the Institute of Cancer Research, London and Imperial College London, who analysed national cancer registry data for England from 2001 to 2019.

In England, around 31,000 cancers were diagnosed in people aged 20 to 49 in 2023, equal to roughly one in every 1,000 people. This compares with 244,000 cases in the 50 to 79 age group, where the rate is around one in 100.

Concerns have been growing in recent years over rising rates of cancers such as bowel and ovarian in younger adults.

Among the younger group, breast cancer was the most common, with 8,500 cases, followed by bowel cancer at 3,000 and melanoma skin cancer with 2,800 diagnoses.

For nine of the 11 cancers identified, rates are rising in younger adults but also increasing in older adults, who are much more likely to develop the disease. Bowel and ovarian cancer were the exceptions, rising only in younger age groups.

The researchers found that bowel cancer rates in younger women linked to BMI rose faster, from 0.9 to 1.6 per 100,000 people, than those not linked to BMI, which rose from 6.4 to 9.6 per 100,000 people. Similar patterns were recorded for men.

However, the authors noted that the overall number of cases of BMI-linked bowel cancer in younger women remained lower than those not linked to BMI, suggesting other factors must be contributing to the increase.

Several suspected contributors, including ultra-processed foods, antibiotic use and air pollution, have been proposed in recent years. However, many of these factors have also shown stable or declining trends in the UK, the team said.

Despite the rise in several cancer rates among younger adults over the past two decades, most established risk factors, including smoking, alcohol consumption, red or processed meat intake, low fibre diets and lack of exercise, remained stable or even declined in the period leading up to diagnosis.

This suggests these traditional risk factors are unlikely to account for much of the increase in cancer cases.

By contrast, overweight and obesity, which have increased steadily since 1995, could be key factors in the rise in cases. The team suggested that between 2001 and 2019, around 20 per cent of the increase in bowel cancer was explained by increases in BMI over that period.

However, the researchers said rises in BMI alone are not enough to explain the overall increase in cancer among younger adults in England and that there are likely to be other causes.

Data also suggest around 15 per cent of bowel cancer in younger people could be linked to being overweight or obese, with around 40 to 50 per cent in total linked to the combined effect of known risk factors such as obesity, lack of exercise, alcohol and smoking.

Montse García-Closas, professor at the ICR, said more research was needed, but “we cannot wait to act”.

She told a media briefing: “Our main conclusion is that although BMI is our best clue, much of the increase still remains unexplained, and we’ve done some additional analysis that show that most likely what’s missing is not just a single cause unexplained, but it’s likely a combination of multiple factors that act together.”

Amy Berrington, professor at the ICR, said: “Although rates have been increasing, cancer in young people is still a rare disease.”

Marc Gunter, professor at Imperial, said obesity was a known risk factor for around 19 different cancers.

He added: “For some of these cancers, including colorectal (bowel) cancer, we think this could be partly caused by higher levels of hormones such as insulin, which is often elevated in people with obesity, as well as inflammation.

“We know people with obesity have higher levels of insulin, and insulin is a growth factor and has been linked to cancer.

“In a recent study, we actually found that insulin in particular might be playing a role in early onset colorectal (bowel) cancer, and this is actually an area of very active research at the moment.”

The researchers called for large, long-term studies to identify all the biological and environmental factors that could explain rising cancer rates in young adults.

García-Closas added: “Tackling obesity across all ages, particularly in children and young people, through stronger public health policies and wider access to effective interventions, could slow the rise in cancer and prevent many cancers and must become a national priority.”

Michelle Mitchell, Cancer Research UK’s chief executive, said: “Globally, and in the UK, we’re seeing a small increase in cancer rates in adults under 50.

“The picture is complex and we need more research to understand what’s driving the trend, but this study helps to fill in some gaps.

“Overweight and obesity doesn’t explain the rise in full though. Improvements in detection are likely to also be playing a part, meaning that more people are being diagnosed at a younger age.

“Preventing cancer cases must be a priority for the UK government. Smoking remains a leading cause of cancer in adults under 50, which is why the Tobacco and Vapes Bill receiving royal assent this week is such a historic moment.

“Measures to restrict the advertising and promotion of junk food, introducing mandatory reporting and targets on healthy food sales, and making nutritious food more accessible to everyone would all help people keep a healthy weight.”

Continue Reading

Diagnosis

WHO launches AI tool for reproductive health information

Published

on

The World Health Organization (WHO) has launched an AI tool in beta to help policymakers, experts and healthcare professionals access sexual and reproductive health information faster.

Called ChatHRP, the tool was created by WHO’s Human Reproduction Programme and draws only on verified research and guidance collected by HRP and WHO.

It uses natural language processing and retrieval-augmented generation to produce referenced content and cut the time spent searching through documents across different platforms and databases.

WHO said ChatHRP also has multilingual capabilities and low-bandwidth functionality to support use in a wide range of settings.

The beta-testing phase is aimed at a broad professional audience, including policymakers, healthcare workers, researchers and civil society groups.

WHO said the tool can help users quickly access up-to-date evidence, find sources for academic work and verify information on sexual and reproductive health and rights.

Examples of questions it can answer include the latest violence against women data in Oceania for women aged 15 to 49, recommendations on managing diabetes during pregnancy, and whether PrEP and contraception can be used at the same time. PrEP is medicine used to reduce the risk of getting HIV.

WHO added that the system will be updated regularly as new HRP materials are published and includes a feedback loop so users can flag gaps in the information provided.

The launch comes amid wider concern about misinformation in sexual and reproductive health.

A 2025 scoping review found that misinformation in digital spaces is a systemic issue that can undermine human rights, reinforce discriminatory social norms and exclude marginalised voices.

The review also said misinformation can affect health systems by shaping provider knowledge and practice, disrupting service delivery and creating barriers to equitable care.

WHO said ChatHRP is intended to give users streamlined access to reliable information as a counter to “algorithms, opinions, or misinformation”.

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.